Pancreatic Cancer Research

ResearcherWenzhou Medical UniversityActive in the last 2 years

Shengzhang Lin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8815-3719; OpenAlex author ID A5069288315. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
16
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 8

  1. Rg3 inhibits hypoxia-induced tumor exosomes from boosting pancreatic cancer vasculogenic mimicry through the HIF-1α/LARS1/mTOR axis. Last author DOI 10.1016/j.phymed.2025.156437↗
  2. Ginsenoside Rg3 suppresses vasculogenic mimicry by impairing DVL3-maintained stemness via PAAD cell-derived exosomal miR-204 in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.phymed.2024.155402↗
  3. High expression of MMP28 indicates unfavorable prognosis in pancreatic cancer. Last author DOI 10.1097/md.0000000000025320↗
  4. Prognostic Biomarkers and Immunotherapeutic Targets Among CXC Chemokines in Pancreatic Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.711402↗
  5. Ginsenoside Rg3 inhibition of vasculogenic mimicry in pancreatic cancer through downregulation of VE‑cadherin/EphA2/MMP9/MMP2 expression. Last author DOI 10.3892/ijo.2014.2500↗
  6. Involvement of endoplasmic reticulum stress in capsaicin-induced apoptosis of human pancreatic cancer cells. Co-author DOI 10.1155/2013/629750↗
  7. Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway. Last author DOI 10.7150/ijbs.8.1↗
  8. Antitumor and apoptosis-promoting properties of emodin, an anthraquinone derivative from Rheum officinale Baill, against pancreatic cancer in mice via inhibiti… Co-author DOI 10.3892/ijo.2011.1147↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhaohong Wang · 5 shared papers, 2012–2025 · strength 0.69
  2. Heqi Bu · 3 shared papers, 2013–2025 · strength 0.62
  3. Xufan Cai · 2 shared papers, 2024–2025 · strength 0.58
  4. Jiacheng Huang · 2 shared papers, 2021 · strength 0.32
  5. Tingting Zhao · 1 shared paper, 2025 · strength 0.30
  6. Kuiwu Ren · 1 shared paper, 2021 · strength 0.16
  7. Zhitao Chen · 1 shared paper, 2021 · strength 0.16
  8. Zhitao Chen · 1 shared paper, 2021 · strength 0.16
  9. Hongfei Tong · 3 shared papers, 2012–2014 · strength 0.11
  10. Hui Chen · 1 shared paper, 2014 · strength 0.04
  11. Jing-Qiang Guo · 1 shared paper, 2014 · strength 0.04
  12. Liang Chen · 1 shared paper, 2014 · strength 0.04
  13. Jian-Hong Zhang · 1 shared paper, 2013 · strength 0.03
  14. Dian-Lei Liu · 1 shared paper, 2012 · strength 0.03
  15. Hongchun Guo · 1 shared paper, 2012 · strength 0.03
  16. Weitian Wei · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.